Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 7377 - 7384 of 12007 results

FDA’s Enforcement Priorities Likely to Change in 2017 and Other “Unknowable Knowns”

January 17, 2017| Blog| Viewpoint

European Unified Patent Court Roll-Out Planned For 2017

January 17, 2017| Blog| Viewpoint

Losing IPR Petitioners May Lack Standing To Appeal

January 17, 2017| Blog| Viewpoint

USCIS Parole Rule: A Practical Solution For Entrepreneurs

January 17, 2017| News

The Management RFP: Shortcut or Shortsighted?

January 17, 2017| News

Sale-Leasebacks: Cash Out but Keep Control

January 17, 2017| News

Offensive TMs At High Court: Everything You Need To Know

January 17, 2017| News

Mintz Nabs Ex-Dechert IP Partner In Silicon Valley

January 17, 2017| News

News & Press Releases

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering

July 08, 2025

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“

Mintz Advises S2G Investments on $40M Series B Financing of Sojo Industries

July 07, 2025

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz Advises Syntis Bio on $33 Million Series A Financing

July 02, 2025

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

View all News and Press Releases